Ianalumab Explained

Type:	mab
Source:	u
Target:	BAFF receptor
Cas Number:	1929549-92-7
Atc Prefix:	none
Kegg:	D12151
Unii:	ZN2GQ3II96
Synonyms:	VAY736

Ianalumab (INN;^[1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus.^{[2] [3] [4]}

This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/III trials. In June 2023 ianalumab was involved in 22 clinical trials, of which 3 were completed, 14 were ongoing, 1 was planned, and 4 were terminated.^[5]

Notes and References

1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117 . WHO Drug Information . 31 . 2 . 2017 .
2. Web site: Ianalumab - MorphoSys/Novartis . AdisInsight . Springer Nature Switzerland AG .
3. van den Hoogen LL, van Laar JM . Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome . Best Practice & Research. Clinical Rheumatology . 34 . 1 . 101485 . February 2020 . 32067925 . 10.1016/j.berh.2020.101485 . free .
4. Narain S, Berman N, Furie R . Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis . Current Opinion in Rheumatology . 32 . 6 . 609–616 . November 2020 . 33002950 . 10.1097/BOR.0000000000000754 . 222150641 .
5. Web site: Risk Adjusted Net Present Value: What is the current valuation of Novartis's Ianalumab . Pharmaceutical Technology . 30 June 2023 .